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Introduction
Upon differentiation, cells stop proliferating and withdraw from 
the cell cycle. Terminal cell cycle exit and differentiation are 
highly orchestrated processes regulated by a complex network of 
molecular pathways. Key regulators of these processes are the E2F 
transcription factors, which, in concert with members of the reti-
noblastoma family (pRb, p107 and p130), control the expression 
of genes involved in cell cycle progression. The E2F protein fam-
ily is composed of eight members, E2F1 to E2F8, which are clas-
sified into activators and repressors based on their transcriptional 
regulatory activities.1,2 E2F1 to E2F3 are considered as activa-
tors, whereas E2F4 to E2F8 are repressors. Generally, activating 
E2F transcription factors drive cell cycle progression by inducing 
the expression of pro-proliferating genes, while repressing E2F 
transcription factors block cell cycle progression by inhibiting the 
expression of these genes.
E2F3 is the only E2F family member whose locus (6p22.3) 
is amplified in human tumors. Amplification and overexpres-
sion of E2F3 is found in lung, bladder, prostate and ovarian 
cancers.3-6 The E2F3 locus encodes two isoforms: E2F3A and 
E2F3B, which are distinguished exclusively by their N termini.7-9 
Two distinct promoters control the expression of alternative first 
exons that are spliced to a common second exon. As a result, 
the two E2F3 isoforms are identical at the regions encoding for 
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their known functional parts. However, E2F3A and E2F3B do 
not have complete functional overlap. Indeed, during cell cycle, 
E2F3A shows a peak of expression in S phase, whereas E2F3B is 
expressed throughout the cell cycle and in G
0
 cells.8
Cells employ numerous ways to tightly regulate the activity of 
E2F3, both at the transcriptional and post-transcriptional level, 
emphasizing the importance of accurately controlling the activity 
of E2F3. The regulation of E2F3 protein turnover is another way 
to control the activity of E2F3;10 however, the molecular mecha-
nisms regulating E2F3 degradation are currently unknown. Here, 
we report that the anaphase-promoting complex/cyclosome tar-
gets E2F3 for ubiquitin-mediated degradation in quiescent cells, 
thus identifying a novel way to control E2F3 activity in cells.
Results
Proteasome-dependent degradation of E2F3 in cells exiting the 
cell cycle. We examined the expression of both E2F3 isoforms 
(E2F3A and E2F3B) during cell cycle exit. Asynchronously 
growing T98G cells (revertants from T98 glioblastoma cells that 
acquired the property to accumulate in G
0
/G
1
 in low serum) 
were serum-deprived to allow cell cycle exit, and protein levels 
were analyzed by immunoblotting. We found that E2F3A lev-
els steadily decreased; E2F3B and E2F4 remained unchanged, 
whereas, as expected, p27 levels increased (Fig. 1). Treatment with 
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of the primary sequence of E2F3A (NCBI Reference Sequence 
NP_001940.1) revealed the presence of four RxxL motifs at 
amino acids 36–39 (D-box I), 109–112 (D-box II), 135–138 
(D-box III) and 158– 161 (D-box IV) that could potentially 
serve as D-boxes (Fig. 4B). E2F3B contains only the putative 
D-box III and D-box IV. To test whether any of these regions 
is required for the interaction of E2F3 with Cdh1, we generated 
D-box mutants of E2F3 in which the arginine and leucine amino 
acids were replaced by alanine. As shown in Figure 4C, all four 
E2F3A D-box mutants and the two D-box mutants of E2F3B are 
still able to interact with Cdh1, suggesting that none of these four 
RxxL motifs is required for the binding of E2F3 to Cdh1.
APC/CCdh1 ubiquitylates E2F3 in vitro. To test whether 
E2F3 is ubiquitylated by APC/CCdh1, we reconstituted the 
ubiquitylation of E2F3 in vitro. As shown in Figure 5, in vitro-
transcribed/translated E2F3A was ubiquitylated in the presence 
of E1, UBCH10, Cdh1 and ubiquitin, although some E2F3A 
ubiquitylation was present in the absence of Cdh1. This is likely 
due to the presence in the rabbit reticulocyte lysate of endog-
enous APC/C and Cdh1 that can contribute to the ubiquity-
lation of APC/C targets.15 The same results were obtained when 
we used E2F3B as a substrate in the ubiquitin conjugation reac-
tion (data not shown). Thus, in agreement with our findings 
in vivo, the in vitro results indicate that Cdh1 promotes E2F3 
ubiquitylation.
Silencing of Cdh1 by RNA interference induces stabiliza-
tion of E2F3 during neuronal differentiation. The finding that 
E2F3A and E2F3B become unstable in cell undergoing quies-
cence prompted us to test whether E2F3 is targeted for degra-
dation during neuronal differentiation, a process regulated by 
APC/CCdh1.16-18 To this aim, we employed human neuroblastoma 
SK-N-SH cells induced to differentiate with retinoic acid. We 
found that in differentiating neuroblastoma cells, the levels of 
E2F3A decreased steadily, whereas the levels of E2F3B did not 
change (Fig. 6A and B). As expected, levels of cyclin A decreased 
and levels of p27 increased as cells exit the cell cycle and differ-
entiate. To test if Cdh1 plays a role in the degradation of E2F3A 
during neuronal differentiation, we silenced the expression of 
Cdh1 in SK-N-SH cells using a previously validated siRNA oli-
gonucleotide.12,19,20 SK-N-SH cells were then treated with retinoic 
acid, and the expression levels of E2F3A and E2F3B were exam-
ined at various time points thereafter. As shown in Figure 6C, 
Cdh1 knockdown reduced the degradation of E2F3A and 
induced accumulation of E2F3B in differentiating neuroblas-
toma cells. In contrast, Cdc20 siRNA did not have any effect on 
the abundance of E2F3A and E2F3B. Together, these results sug-
gest a role for APC/CCdh1 in mediating the degradation of E2F3A 
and E2F3B in differentiating neuroblastoma cells.
Discussion
APC/CCdh1 governs the G
1
 and G
0
 phases of the cell cycle by tar-
geting a number of key substrate proteins for degradation.11,21 In 
the present report, we show that APC/CCdh1 controls the stability 
of the E2F3 transcription factor during cell cycle exit. We dem-
onstrate that E2F3 physically interacts with Cdh1 but not with 
the proteasome inhibitor MG132 prevented E2F3A downregula-
tion, suggesting that its decrease in response to serum depriva-
tion is at least partially due to protein degradation. Surprisingly, 
MG132 also induced the accumulation of E2F3B.
Cdh1 targets E2F3 for proteasome-dependent degradation. 
The finding that E2F3A is degraded in cells undergoing quies-
cence suggests that the degradation of E2F3A may be mediated by 
the APC/CCdh1, a crucial regulator of the G
0
 phase.11 To test this 
hypothesis, we transfected asynchronous T98G cells with a con-
struct expressing either HA-tagged E2F3A (Fig. 2A), HA-tagged 
E2F3B (Fig. 2B) or HA-tagged Skp2 (Fig. 2C), together with 
a construct expressing either FLAG-tagged Cdc20 or FLAG-
tagged Cdh1. Ectopic expression of Cdh1, but not Cdc20, led to 
a decrease in the steady-state levels of both E2F3A and E2F3B. 
Similarly, Skp2, a known substrate of APC/CCdh1,12,13 was down-
regulated upon Cdh1 ectopic expression. To test if E2F3A and 
E2F3B downregulation was due to proteasome-dependent degra-
dation, the proteasome inhibitor MG132 was added to cells over-
expressing Cdh1. As shown in Figure 3, proteasomal inhibition 
prevents Cdh1-dependent downregulation of E2F3A and E2F3B. 
Altogether, these results demonstrate that APC/CCdh1 targets 
both E2F3A and E2F3B for proteasome-dependent degradation.
E2F3A and E2F3B interact with Cdh1 but not with Cdc20. 
We next tested whether Cdh1 physically interacts with the two 
E2F3 isoforms. HEK293T cells were transfected with a con-
struct expressing FLAG-tagged Cdc20 or FLAG-tagged Cdh1. 
FLAG immunoprecipitations were then performed to exam-
ine the binding of Cdh1 and Cdc20 to E2F3A and E2F3B. 
Endogenous E2F3A and E2F3B coimmunoprecipitated with 
FLAG-tagged Cdh1, but not with FLAG-tagged Cdc20 (Fig. 
4A). These results demonstrate that both E2F3A and E2F3B 
interact with the APC/C activator Cdh1. Degradation of many 
APC/C substrates depends on a destruction motif (D-box) with 
the consensus sequence RxxLxxIxN;14 however, many APC/C 
substrates contain only a minimal D-box (RxxL).12,13 Analysis 
Figure 1. e2F3A and e2F3B are targeted for proteasome-dependent 
degradation in cells withdrawing from the cell cycle. Asynchronous 
t98G glioblastoma cells were deprived of serum for the indicated times. 
Where indicated, the proteasome inhibitor MG132 (10 μM) was added 
for the last 5 hours. Cells were collected and lysed. Whole cell extracts 
were analyzed by immunoblotting with antibodies for the indicated 
proteins. Skp1 was blotted as a loading control.
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Furthermore, it is well established that while E2F3A induces the 
expression of genes involved in cell cycle progression, E2F3B con-
trols genes involved in differentiation and development. The rea-
son for the ubiquitin-mediated degradation of E2F3B in absence 
of an effect on its steady-state level in quiescent cells is currently 
unknown. In conclusion, Cdh1-mediated degradation of E2F3 
during cell cycle exit represents a novel mechanism to control 
E2F3 abundance.
Experimental Procedures
Cell lines, synchronization method and drug treatments. All 
cells were obtained from ATCC. Human embryonic kidney 
HEK293T and human glioblastoma T98G cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM); human neu-
roblastoma SK-N-SH cells were cultured in Dulbecco’s modified 
Eagle’s medium/F12 (DMEM/F12). Both cell culture media were 
supplemented with 10% v/v Fetal Calf Serum (FCS), 100 U/ml 
Penicillin/Streptomycin and 2 mM L-Glutamine. All cells were 
maintained in a humidified 37°C incubator with 5% CO
2
. The 
proteasome inhibitor MG132 (10 μM) was added to HEK293T 
and T98G cells 5 h prior to cell collection. T98G cells were 
the related APC/C activator Cdc20. We also show that APC/
CCdh1 is able to ubiquitylate E2F3A in vitro, and that the degrada-
tion of E2F3A is stimulated by Cdh1, but not by Cdc20. Finally, 
we demonstrate that Cdh1 knockdown stabilizes E2F3 during 
cell cycle exit and neuronal differentiation of human neuroblas-
toma cells.
Additional studies will be required to identify the region 
of E2F3 that mediates the binding between E2F3 and Cdh1. 
We have shown that the RxxL motifs present in E2F3 are not 
required for E2F3 binding to Cdh1. In the accompanying paper, 
Budhavarapu et al. report that E2F1 interacts directly with Cdh1 
via its C-terminal region. Due to the structural and functional 
similarities between E2F1 and E2F3, it is interesting to speculate 
that a yet-to-be-identified region at the C terminus of E2F3 might 
be required for the degradation of both E2F3A and E2F3B.
The finding that APC/CCdh1 regulates the stability of the 
E2F3B isoform in quiescent cells is somehow surprising. Indeed, 
our data indicate that during cell cycle exit, E2F3A levels steadily 
decrease, while E2F3B levels remain unchanged. This is in 
agreement with other studies8,22 showing that E2F3A is mostly 
expressed in growing cells, with enrichment in S phase, whereas 
E2F3B is expressed both in proliferating and in quiescent cells. 
Figure 2. Degradation of e2F3A and e2F3B is stimulated by Cdh1, but not by Cdc20. t98G cells were co-transfected with plasmids expressing HA-
tagged e2F3A, HA-tagged e2F3B or HA-tagged Skp2, along with FLAG-tagged Cdc20, FLAG-tagged Cdh1 or an empty vector (eV). A plasmid express-
ing eGFp was co-transfected as a marker of transfection. Cells were lysed and e2F3A (A), e2F3B (B), Skp2 (C) together with Cdh1 or Cdc20 were detected 
by immunoblotting using anti-HA and anti-FLAG antibodies, respectively. Actin was blotted as a loading control. the asterisks (*) indicate nonspecific 
bands. Graphs on the right show quantification e2F3A (A), e2F3B (B) and Skp2 (C) expression. the value given for the amount of protein present in the 
control sample (eV) was set as 1 (n = 3).
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Following SDS-PAGE, separated proteins were transferred onto 
pre-activated PVDF membrane (Millipore). After transfer, 
the PVDF membrane was stained with Ponceau Red Solution 
(Sigma-Aldrich) to confirm transfer efficiency and equal loading. 
The PVDF membrane was washed in phosphate-buffered saline 
containing 0.1% v/v Tween 20 (PBS-T) to remove the Ponceau 
red stain, blocked for 1 h at room temperature in 5% w/v low-
fat dried milk dissolved in PBS-T and probed with various 
antibodies. Incubation with the appropriate primary antibody 
was done in 5% w/v low-fat dried milk dissolved in PBS-T for 
2 h at room temperature. Mouse monoclonal antibodies were 
from Invitrogen (Cul1), Covance (anti-HA), Sigma-Aldrich 
(anti-FLAG and anti-Cdc27), BD Transduction Laboratories 
(anti-p27), Thermo Scientific (anti-Cdh1) and Santa Cruz 
Biotechnology or Bethyl Laboratories (anti-Actin). Rabbit poly-
clonal antibodies were from Santa Cruz Biotechnology (anti-
cyclin A, anti-E2F3, anti-Skp1 and anti-Cdc20). After three 
washes in PBS-T, the membranes were incubated with horserad-
ish peroxidase-linked secondary antibodies (GE Healthcare) in 
5% w/v low-fat dried milk dissolved in PBS-T and then washed 
three times in PBS-T. Proteins were visualized by an enhanced 
chemiluminescence detection system (Thermo Scientific) 
according to the manufacturer’s instructions.
Mammalian expression plasmids and transfection. E2F3A, 
E2F3B, Skp2, Cdh1 and Cdc20 cDNAs were cloned in 
pcDNA3.1. E2F3A, E2F3B and Skp2 were HA-tagged, whereas 
Cdh1 and Cdc20 were FLAG-tagged. Transfection by calcium 
phosphate was performed as follows. Exponentially growing 
synchronized by serum starvation. Cells were washed three times 
with PBS and supplied with serum starvation medium (DMEM 
supplied with 0.02% v/v FCS, 2 mM L-glutamine) and incu-
bated for 48 h. Subsequently, the culture medium was replaced 
with DMEM supplied with 20% v/v FCS, 2 mM L-Glutamine, 
and cells were collected at the indicated time points. Neuronal 
differentiation was induced by treating SK-N-SH cells with 10 
μM retinoic acid (Sigma-Aldrich).
Biochemical methods. Cell extracts were prepared as fol-
lows: cell monolayers were washed twice with room tempera-
ture PBS and harvested. Cells were lysed in Triton Lysis Buffer 
(0.1% Triton-X100, 50 mM TRIS-HCl pH 7.4, 0.25 M NaCI, 
1 mM EDTA, 50 mM NaF) supplied with the following: 0.1 
mM phenylmethyl sulfonylflouride (PMSF), 1 mM dithioth-
reitol (DTT), 0.1 mM sodium orthovanadate (NaV), 10 mg/ ml 
tosyl phenylalanyl chloromethyl ketone (TPCK), 10 μg/ml 
tosyl lys chloromethyl ketone (TLCK) and a mixture of 1 μg/
ml leupeptin, 10 μg/ml soybean trypsin inhibitor and 1 μg/ml 
aprotinin.
For immunoprecipitations, HEK293T cells from one 15-cm 
plate were lysed in TLB as described above. Cell extracts were 
precleared by adding 40 μl Protein-G Sepharose (Invitrogen) and 
incubated for 1 h. Precleared cell extracts were then incubated 
with FLAG resin (Sigma-Aldrich) for 3 h. Immunoprecipitates 
were washed with 1 ml of TLB four times. After the last wash, 
immunoprecipitates were resuspended in Laemmli sample buf-
fer and boiled for 4 min at 90°C for denaturation. For western 
blot analysis, protein samples were separated by SDS-PAGE. 
Figure 3. Cdh1-dependent degradation of e2F3 is prevented by proteasomal inhibition. t98G cells were co-transfected with plasmids expressing 
either HA-tagged e2F3A or HA-tagged e2F3B, along with either FLAG-tagged Cdh1 or an empty vector (eV). A plasmid expressing eGFp was co-trans-
fected as a marker of transfection. Where indicated, cells were treated with 10 μM MG132 for 5 hours before harvesting. Cells were lysed and e2F3A 
(A) and e2F3B (B), together with Cdh1, were detected by immunoblotting using anti-HA or anti-FLAG antibodies, respectively. Actin was blotted as a 
loading control. Graphs on the right show quantification of e2F3A (A), e2F3B (B) expression. the value given for the amount of protein present in the 
control sample (eV) was set as 1 (n = 3).
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HEK293T cells were plated in 15-cm plates one day before 
transfection, so that cells were 70–80% confluent by the time of 
transfection. Cells were transfected with 25 μg of plasmid and 
1 μg of EGFP (as a transfection control). Plasmids were diluted 
in 250 mM CaCl
2
, incubated for 5 min at room temperature 
and mixed with 2x BBS (50 mM BES pH 6.96 [N-N-Bis(2-
hydroxyethyl)-2-aminoethanesulfonic acid], 280 mM NaCl, 
1.5 mM Na
2
HPO
4
) and incubated for 20 min. Transfection 
mixtures were then added dropwise to the cells. Culture media 
was replaced with fresh DMEM 5 h after transfection. Cells 
were collected and lysed 48 h after transfection. T98G cells 
were transfected by Metafectene (Biontex Laboratories GmbH) 
according to the manufacturer’s instructions. When indicated, 
10 μM MG132 was added to inhibit proteasome-dependent 
degradation.
Gene silencing by small interfering RNA. The sequences of 
the siRNA oligonucleotides targeting Cdh1 and Cdc20 were: 
Figure 4. Cdh1, but not Cdc20, interacts with e2F3A and e2F3B. (A) HeK293t cells were transfected with either empty vector (eV), FLAG-tagged Cdc20 
or FLAG-tagged Cdh1. the proteasome inhibitor MG132 (10 μM) was added 5 hours before harvesting. Cells were lysed and whole cell extracts (WCe) 
were subjected either to immunoblotting or immunoprecipitation (Ip) with anti-FLAG resin and subsequent immunoblotting for the indicated proteins. 
(B) Alignment of amino acid regions of putative destruction box motifs in e2F3A with the D-box motifs of known substrates of ApC/CCdh1. (C) HeK293t 
cells were transfected with FLAG-tagged Cdh1 along with the indicated Myc-tagged e2F3A and e2F3B mutants. Cells were lysed and whole cell extracts 
were subjected either to immunoblotting or immunoprecipitation (Ip) with anti-Myc resin and subsequent immunoblotting for the indicated proteins.
Figure 5. e2F3 is ubiquitylated by ApC/CCdh1. In vitro ubiquitylation 
assay of 35S-labeled, in vitro translated e2F3A was performed with 
immunopurified ApC/C, e1, UBCH10 and ubiquitin in the presence or 
absence of Cdh1 translated in vitro. Samples were incubated at 30°C for 
the indicated times and analyzed by SDS-pAGe followed by autoradiog-
raphy. the bracket on the right side marks a ladder of bands corre-
sponding to polyubiquitylated e2F3A.
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3 h at 4°C. Protein G-agarose was then added and incubated 
for 45 min at 4°C on a rotating wheel. The beads were washed 
four times in Triton buffer and four times in QA buffer (10 mM 
TRIS-HCl pH 7.5, 100 mM KCl, 1 mM MgCl
2
, 0.1 mM CaCl
2
, 
1 mM DTT). The resulting beads were used for two reactions 
of in vitro ubiquitylation. Ubiquitylation assays were performed 
in a volume of 10 μl containing 50 mM Tris pH 7.6, 5 mM 
MgCl
2
, 0.6 mM DTT, 2 mM ATP, 2 μl in vitro transcribed/
5'-AAT GAG AAG TCT CCC AGT CAG-3' and 5'-AAA CCT 
GGC GGT GAC CGC TAT-3', respectively. SK-N-SH cells 
were transfected with the oligos twice, at 24 and 48 h after plat-
ing using Metafectene (Biontex Laboratories GmbH) according 
to the manufacturer’s instructions.
In vitro ubiquitylation assay. Ubiquitylation assays were 
performed as previously described.12 Briefly, an anti-Cdc27 anti-
body was added to cell extracts and incubated for approximately 
Figure 6. Cdh1 silencing stabilizes e2F3 during neuronal differentiation. (A) SK-N-SH neuroblastoma cells were treated with 10 μM retinoic acid (RA) 
to induce neuronal differentiation. At the indicated times, cells were collected and lysed. Whole cell extracts were analyzed by immunoblotting with 
antibodies for the indicated proteins. phase contrast images of all samples were taken at 10x magnification before harvesting (B). (C) Cdh1 silencing 
stabilizes e2F3A and e2F3B during neuronal differentiation. SK-N-SH cells were transfected twice with siRNA targeting a non-relevant mRNA (control 
siRNA), Cdh1 mRNA or Cdc20 mRNA. After transfection, 10 μM retinoic acid was added to induce neuronal differentiation. Cells were collected at the 
indicated time points and analyzed by immunoblotting with antibodies for the indicated proteins. Actin was blotted as a loading control.
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translated unlabelled Cdh1, 50 ng/μl E1 (Boston Biochem), 100 
ng/μl Ubc1, 100 ng/μl Ubc10, 2.5 μg/μl ubiquitin (Sigma), 1 
μM ubiquitin aldehyde and 1 μl 35S-methionine-labeled in vitro 
transcribed/translated E2F3. The reactions were incubated at 
30°C for the indicated times and analyzed by SDS-PAGE and 
autoradiography.
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